Publication | Closed Access

The combination of bortezomib, melphalan, dexamethasone and intermittent thalidomide is an effective regimen for relapsed/refractory myeloma and is associated with improvement of abnormal bone metabolism and angiogenesis

Hematological MalignancyOncologyRelapsed/refractory MyelomaIntermittent ThalidomideMedicineHematologyPharmacotherapyPharmacologyAbnormal Bone MetabolismMyeloid Neoplasia